Medical/Pharmaceuticals
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2026-01-09 08:00
1717
MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- MediLink Therapeutics ("MediLink") today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational novel antib...
2026-01-09 08:00
1210
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer,John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will ...
2026-01-08 22:00
1407
Chinese Medical AI Team's MedGPT Tops Global Rankings in New Clinical Benchmark Published by Nature Portfolio Journal
BEIJING, Jan. 8, 2026 /PRNewswire/ -- A research team from China has introduced the first standardized framework for evaluating the clinical applicability of medical AI systems, with their findings published in npj Digital Medicine, a leading journal in the Nature Portfolio ranked in the top tier...
2026-01-08 14:51
2310
Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer
SEATTLE, Jan. 7, 2026 /PRNewswire/ -- Arbele, a biotechnology company focused on developing innovative targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARB1002, its investigational antibody-drug conjugate (ADC...
2026-01-08 00:00
2288
Sensura to Showcase Non-Invasive Health Monitoring Platform, Starting with Glucose, at CES 2026
LAS VEGAS, Jan. 6, 2026 /PRNewswire/ -- Sensura, a Singapore-based deep-tech company focused on next-generation health and wellness monitoring, today announced that it will showcase its non-invasive health monitoring platform, starting with glucose, atCES 2026, taking place from January 6–9, 2026...
2026-01-07 11:18
2332
Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update inChina for its internally developed, first-in-class PD-1/VEGF bispecific antibody, ivonescimab. The updated label incorporates final a...
2026-01-07 10:50
3329
Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies
CHENGDU, China, Jan. 6, 2026 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference (JPMHC) will be held inSan Francisco, California, USA, from January 12 to 15, 2026. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) has been invited to attend the ...
2026-01-07 10:44
3109
HealthBiome Achieves Dual Regulatory Milestones: FDA NDI Acknowledgment and Korean MFDS Approval for HB05P Muscle Health Ingredient
Akkermansia muciniphila postbiotic receives both U.S. FDA dietary supplement clearance and Korean functional ingredient approval with muscle health claim, positioning HealthBiome for dual-market launch in 2026 DAEJEON, South Korea, Jan. 6, 2026 /PRNewswire/ -- HealthBiome Inc., a pioneering stri...
2026-01-07 08:00
2375
Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference
INCHEON, South Korea, Jan. 6, 2026 /PRNewswire/ -- Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced that Jin-Seok Seo, Chief Executive Officer andHyuk-Jae Lee, Senior Executive Vice President at Celltrion, will present at the 44th Annual J.P. Morgan Healthc...
2026-01-07 07:42
3803
Nuon Medical Unveils Tech-Integrated Packaging Ecosystem at CES 2026, Engineering Clinical Precision into the Point of Skin Contact
LAS VEGAS, Jan. 6, 2026 /PRNewswire/ -- Nuon Medical, a leader in beauty tech
innovation, has announced a comprehensive tech-integrated packaging ecosystem
at CES 2026.
2026-01-07 01:00
185
Mind With Heart Robotics Showcases Emotionally Intelligent Robot Lineup at CES 2026, Including CES Innovation Award Honoree An'An Biomimetic Affective AI Panda
Company Expands Therapeutic Robotics Comprehensive Product Lineup Addressing Diverse Emotional and Clinical Support Needs LAS VEGAS, Jan. 6, 2026 /PRNewswire/ -- Mind With Heart Robotics Co., Ltd. showcases its comprehensive lineup of emotionally intelligent robots that mimic natural movements, ...
2026-01-07 01:00
482
Expanding Healthcare Access for Women's Health -- Noul Unveils AI-Automated Cervical Cancer Diagnostics Solution at CES 2026
* Dramatically cuts diagnostic workflows by 80%…delivering results in under 20 minutes * Decentralized, fully automated diagnostic model helps reduce healthcare infrastructure gaps and supports WHO's 2030 cervical cancer screening goals * Eco-friendly, sustainable AI diagnostics with NGSI so...
2026-01-07 01:00
273
VivaVision Biotech Receives Positive Written Feedback from FDA - VVN461HD New Drug Application (NDA) Requires Only a "Single Phase III" Pivotal Clinical Study in the U.S. for Non-Infectious Anterior Uveitis Treatment
WENZHOU, China, Jan. 6, 2026 /PRNewswire/ -- Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced that it has received the written meeting minutes from the U.S. Food and Drug Administration (F...
2026-01-07 00:00
134
Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum
BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today announceddosing of the first patient in the Phase Ib clinical trial of BBT002, a novel platform-in-a...
2026-01-06 22:30
168
Terumo Launches SurTract™ Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR® Passive Safety Technology
- New, retractable safety hypodermic line offers enhanced safety, reliability and ease of use while minimizing patient discomfort* - SOMERSET, N.J., Jan. 6, 2026 /PRNewswire/ -- Terumo Medical Corporation, a wholly-owned subsidiary of Terumo Corporation, announced the US launch of its SurTract™ ...
2026-01-06 21:29
1232
Zpeer Launches A-DHA-PT™, a High-Concentration DHA Supplement for Dogs, and Announces Research Collaboration with the University of Tokyo
TOKYO, Jan. 6, 2026 /PRNewswire/ -- Zpeer Inc. (Headquarters: Shibuya, Tokyo; CEO:Toshiya Morino), an animal health company focused on evidence-based therapeutic innovation, has recently announced the launch of A-DHA-PT™ (pronounced "ay-dapt"), a high-concentration DHA supplement designed to supp...
2026-01-06 21:00
192
Xellar and WOOJUNG BIO Announce Multi-Year Strategic Partnership to Advance AI-Enabled Hybrid Human Organ-on-a-Chip (OoC)-Animal Preclinical Platforms
BOSTON and SEOUL, South Korea, Jan. 5, 2026 /PRNewswire/ -- Xellar Biosystems ("Xellar"), a globally leading innovator in next-generation artificial intelligence- and computer vision–assisted, organ-on-a-chip–based drug discovery and development platforms, today announced that it has entered into...
2026-01-06 08:00
2283
Nanjing Delova Announces Statistically Significant and Clinically Meaningful Results From Two Phase 3 Trials of QP-6211 for the Treatment of Postoperative Pain
* Treatment with QP-6211 achieved primary and all key secondary endpoints in both placebo- and active-controlled Phase 3 trials following hemorrhoidectomy or bunionectomy. * QP-6211 demonstrated statistically significant reductions in postoperative pain and opioid consumption through 72 hou...
2026-01-05 23:00
2276
Flat Medical Appoints Eric Steen, Former B. Braun Executive, as Strategic Advisor
Medical Device Industry Veteran to Guide Capital Strategy and Market Expansion AUSTIN, Texas and TAIPEI, Jan. 5, 2026 /PRNewswire/ -- Flat Medical, a leader in precision safety technology for clinical procedures, today announced the appointment ofEric Steen as Strategic Advisor. Mr. Steen brings ...
2026-01-05 21:30
2563
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 321 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03SMU MBA Rises in FT Global Rankings, Excelling in ESG, Salary and Value-for-Money
[Picked up by 260 media titles]
2026-02-16 08:00Most Read
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
8039
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
7320
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
6901
